These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21484351)

  • 21. Short echo time proton magnetic resonance spectroscopy in Alzheimer's disease: a longitudinal multiple time point study.
    Schott JM; Frost C; MacManus DG; Ibrahim F; Waldman AD; Fox NC
    Brain; 2010 Nov; 133(11):3315-22. PubMed ID: 20739347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
    An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
    J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Usefulness of proton and phosphorus MR spectroscopic imaging for early diagnosis of Parkinson's disease.
    Weiduschat N; Mao X; Beal MF; Nirenberg MJ; Shungu DC; Henchcliffe C
    J Neuroimaging; 2015; 25(1):105-10. PubMed ID: 24325203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting.
    Almuqbel M; Melzer TR; Myall DJ; MacAskill MR; Pitcher TL; Livingston L; Wood KL; Keenan RJ; Dalrymple-Alford JC; Anderson TJ
    Parkinsonism Relat Disord; 2016 Jan; 22():54-61. PubMed ID: 26627939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Marked N-acetylaspartate and choline metabolite changes in Parkinson's disease patients with mild cognitive impairment.
    Nie K; Zhang Y; Huang B; Wang L; Zhao J; Huang Z; Gan R; Wang L
    Parkinsonism Relat Disord; 2013 Mar; 19(3):329-34. PubMed ID: 23238068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: a proton magnetic resonance spectroscopy study.
    Ellis CM; Lemmens G; Williams SC; Simmons A; Dawson J; Leigh PN; Chaudhuri KR
    Neurology; 1997 Aug; 49(2):438-44. PubMed ID: 9270574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MRS study on lentiform nucleus in idiopathic Parkinson's disease with unilateral symptoms.
    Zheng XN; Zhu XC; Ruan LX; Zhang LJ; Yuan M; Shang DS; Liu Y
    J Zhejiang Univ Sci; 2004 Feb; 5(2):246-50. PubMed ID: 14674041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease.
    Prasad S; Stezin A; Lenka A; George L; Saini J; Yadav R; Pal PK
    Eur J Neurol; 2018 Apr; 25(4):680-686. PubMed ID: 29341412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature.
    Péran P; Cherubini A; Assogna F; Piras F; Quattrocchi C; Peppe A; Celsis P; Rascol O; Démonet JF; Stefani A; Pierantozzi M; Pontieri FE; Caltagirone C; Spalletta G; Sabatini U
    Brain; 2010 Nov; 133(11):3423-33. PubMed ID: 20736190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease.
    Vaillancourt DE; Spraker MB; Prodoehl J; Abraham I; Corcos DM; Zhou XJ; Comella CL; Little DM
    Neurology; 2009 Apr; 72(16):1378-84. PubMed ID: 19129507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
    Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
    Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is magnetic resonance spectroscopy capable of detecting metabolic abnormalities in neurofibromatosis type 1 that are not revealed in brain parenchyma of normal appearance?
    Rodrigues AC; Ferraz-Filho JR; Torres US; da Rocha AJ; Muniz MP; Souza AS; Goloni-Bertollo EM; Pavarino ÉC
    Pediatr Neurol; 2015 Mar; 52(3):314-9. PubMed ID: 25585912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parkinson's disease: in vivo metabolic changes in the frontal and parietal cortices in 6-OHDA treated rats during different periods.
    Hou Z; Zhang Z; Meng H; Lin X; Sun B; Lei H; Fang K; Fang F; Liu M; Liu S
    Int J Neurosci; 2014 Feb; 124(2):125-32. PubMed ID: 23931110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proton MR spectroscopy in patients with neurofibromatosis type 1: evaluation of hamartomas and clinical correlation.
    Castillo M; Green C; Kwock L; Smith K; Wilson D; Schiro S; Greenwood R
    AJNR Am J Neuroradiol; 1995 Jan; 16(1):141-7. PubMed ID: 7900583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regional variations and age-related changes detected with magnetic resonance spectroscopy in the brain of healthy dogs.
    Ono K; Kitagawa M; Ito D; Tanaka N; Watari T
    Am J Vet Res; 2014 Feb; 75(2):179-86. PubMed ID: 24471754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.
    Frederick BD; Lyoo IK; Satlin A; Ahn KH; Kim MJ; Yurgelun-Todd DA; Cohen BM; Renshaw PF
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1313-22. PubMed ID: 15588758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MR Spectroscopy: A Longitudinal Biomarker for Substantia Nigra Pathology in Parkinson's Disease?
    Öz G
    Mov Disord; 2015 Sep; 30(10):1304-5. PubMed ID: 26184363
    [No Abstract]   [Full Text] [Related]  

  • 38. (1)H spectroscopic imaging of human brain at 3 Tesla: comparison of fast three-dimensional magnetic resonance spectroscopic imaging techniques.
    Zierhut ML; Ozturk-Isik E; Chen AP; Park I; Vigneron DB; Nelson SJ
    J Magn Reson Imaging; 2009 Sep; 30(3):473-80. PubMed ID: 19711396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proton magnetic resonance spectroscopy of brain in congenital myotonic dystrophy.
    Hashimoto T; Tayama M; Yoshimoto T; Miyazaki M; Harada M; Miyoshi H; Tanouchi M; Kuroda Y
    Pediatr Neurol; 1995 May; 12(4):335-40. PubMed ID: 7546006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of metabolic changes in the striatum of a MPTP-intoxicated canine model: in vivo ¹H-MRS study of an animal model for Parkinson's disease.
    Choi CB; Kim SY; Lee SH; Jahng GH; Kim HY; Choe BY; Ryu KN; Yang DM; Yim SV; Choi WS
    Magn Reson Imaging; 2011 Jan; 29(1):32-9. PubMed ID: 20980117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.